Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

The study will be conducted in the US and in Europe and will include paediatric patients
diagnosed with depressive or anxiety disorders of two age populations; children aged 7-11
years and adolescents of the age 12-17 years. It is an open study to allow pharmacokinetic
(PK) sampling of all patients and four dose levels will be tested. Following lower initial
doses for 2 to 6 days, the patients will be treated once daily at the assigned dose levels
for 14 days, and it is expected that patients may benefit from treatment during this period.
As the treatment duration is not sufficient according to treatment guidelines, if judged or
indicated by the investigator, the patients are offered to continue in an extension
treatment of up to six months to allow possibility for therapeutic satisfaction.

Preferably, the cohorts will be dosed in the following order: AC1, AC2, CC1, AC3, CC2, AC4,
CC3, and CC4. An external data safety monitoring board (DSMB) will be established to
evaluate safety, tolerability and preliminary PK data from the dosed cohort(s) prior to any
dosing of subsequent cohort (s). The dose regimen may be adjusted based on the
recommendation of the DSMB. Adolescents will be exposed to a certain dose of vortioxetine
before children receive the same dose.

Inclusion Criteria:

- Patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder.

- The patient and parent(s)/legal representative(s) are able to comprehend and
satisfactorily comply with the protocol requirements.

- Treatment with antidepressant therapy is warranted, as judged by the investigator.

Exclusion Criteria:

- The patient is pregnant or breast-feeding.

- The patient presents or has a history of an Axis I (DSM-IV-TR) diagnosis of Bipolar
Disorder, Post Traumatic Stress Disorder (PTSD), Autism, Pervasive Developmental
Disorder (PDD), Obsessive Compulsive Disorder (OCD) or Schizophrenia or
Schizoaffective Disorder.

- The patient has not maintained a stable dose of a methylphenidate or amphetamine for
their treatment of attention-deficit/hyperactivity disorder (ADHD) for a minimum of 4
weeks prior to the study treatment.

- The patient has a known mental retardation, or clinical evidence or known social or
school history indicative of mental retardation.

- The patient is at significant risk of committing suicide based on history (for
example previous suicide attempt) or according to the investigator's experience, or
based on active suicidal ideation, intent or plan, item 4 or 5 of the
Columbia-Suicide Severity Rating Scale (C-SSRS).

- The subject has any concurrent illness that may affect the particular target or
absorption, distribution, and elimination of the investigational medicinal product
(IMP).

- The patient meets DSM-IV-TR criteria for any psychoactive substance or alcohol use
disorder.

Other inclusion and exclusion criteria may apply.